The Phase II project is to complete development of a new Rolling Joint Prosthetic Leg comprising a Rolling Joint (Free-Flow) Foot and Ankle and the Rolling Joint Prosthetic Knee. Original design of both prostheses is based on a Rolling Joint Technology, recently developed by the applicants. The Rolling Joint Foot and Ankle was commercialized in October of 1999. Major efforts during the Phase I of the current study were developed to design, manufacture and testing of the new Rolling Joint Knee. As results of the Phase I study showed, development of Rolling Joint Prosthetic Leg has merit to be continued. Development and testing of the Rolling Joint Knee will be completed during the Phase II proposed. Additional research will be conducted to verify the hypothesis that patients with trans-femoral amputations will benefit from aan assembly of both Rolling Joint Units in a Rolling Joint Leg. New methodology for individual tuning of critical parameters of prostheses will be developed. It will provide more normal, less painful locomotion in a lower limb amputee and increase number of patients to be managed prosthetically. The specific aims of the Phase II project. Complete a development of a new Knee unit prototype with compliant tibial component; conduct a comparative mechanical tests and biomechanical gait study with 20 trans-femoral amputees to verify the hypothesis that a new prosthetic device with the proposed mechanical outcome improves a trans-femoral amputee gait by normalizing "stump-socket" interface during stance phase of gait. Long term objectives of the proposed research are to develop a functional, reliable and economical prosthetic modular system. PROPOSED COMMERCIAL APPLICATIONS: Potential commercial application is the creation of a product line of Rolling Joint Feet and Knees. The RJ Leg will enhance performance of transfemoral amputees without increasing the cost, thus providing a highly competitive product in the field of prosthetic rehabilitation.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
929
DUNS Number
803723790
UEI
UKLRCJ4QPJH5
Project Start Date
28-September-1999
Project End Date
30-April-2005
Budget Start Date
01-May-2003
Budget End Date
30-April-2005
Project Funding Information for 2003
Total Funding
$362,841
Direct Costs
$327,634
Indirect Costs
$32,763
Year
Funding IC
FY Total Cost by IC
2003
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$362,841
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R44HD038143-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R44HD038143-03
Patents
No Patents information available for 5R44HD038143-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R44HD038143-03
Clinical Studies
No Clinical Studies information available for 5R44HD038143-03
News and More
Related News Releases
No news release information available for 5R44HD038143-03
History
No Historical information available for 5R44HD038143-03
Similar Projects
No Similar Projects information available for 5R44HD038143-03